MetaCap

Longeveron (LGVN) vs Tempest Therapeutics (TPST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

LGVN-31.97%TPST-63.74%
+40%-14%-69%
Oct 7, 20261 yearNov 20, 2026
LGVN-33.06%TPST-62.24%
+4%-31%-65%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

LGVN versus TPST key metrics
MetricLGVNTPST
Share price$1.66$0.287
Market cap$5.60M$5.74M
1-day change-8.79%-6.18%
YTD return—-90.00%
1-year return—-91.80%
5-year return—-99.77%
EPS (TTM)$-7.95$-3.16
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.20M—
Revenue growth (YoY)-49.87%—
Net income (latest FY)$-22.70M$-26.26M
Gross margin66.97%—
Operating margin-1942.20%—
Net margin-1893.58%—
52-week high$12.30$4.22
52-week low$1.31$0.28
Distance from 52-week high-86.50%-93.20%
Analyst consensusnonestrong_buy
Avg. price target upside+3589.76%+2339.02%
Average volume115.35K2.56M
Shares outstanding3.23M20.00M
Employees384
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Longeveron

LGVN stock →

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.

Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees

About Tempest Therapeutics

TPST stock →

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

LGVN vs TPST FAQ

Which is bigger, Longeveron or Tempest Therapeutics?

Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.60M for Longeveron (LGVN).

Are Longeveron and Tempest Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons